Pfizer CentreOne launches Enviero green-chemistry progesterone API
Carbon footprint reduced by more than 70%.
Pfizer CentreOne has introduces Enviero progesterone into the API marketplace. Enviero progesterone is produced by a first-of-its-kind progesterone synthesis developed by Pfizer that reduces waste, greenhouse gas emissions and use of hazardous solvents. Results include cutting the carbon footprint of the progesterone manufacturing process by more than 70% and eliminating the use of metal catalysts. Pfizer CentreOne is a global contract manufacturing organization embedded within Pfizer Inc. and a leading supplier of steroid and hormone APIs and intermediates.
"Enviero green-chemistry progesterone represents a step change in progesterone API synthesis,” said Greg Scanlon, API business lead for Pfizer CentreOne. “And it’s in keeping with Pfizer’s commitment to reduce its impact on the environment.” Developed over 12 years, Enviero progesterone is manufactured via a proprietary biocatalytic process based on plant sterols. Scanlon continued: “We are pleased to offer Enviero progesterone to customers looking for a reliable supply of high-quality progesterone for their medicines."
Validated process
While new to Pfizer CentreOne customers, Enviero progesterone has been used by Pfizer as an intermediate in the manufacture of its own medications for the past 4 years. More than 500 metric tons have been manufactured to date for internal use.
The compound is manufactured exclusively in the US at Pfizer’s Kalamazoo, Michigan, facility. As with all Pfizer CentreOne APIs, all processing steps for Enviero progesterone are performed under Pfizer’s stringent quality management system, and the compound is backed by technical and regulatory support for the life of the product.
Green chemistry
Enviero progesterone is the first API to be launched from Pfizer CentreOne’s green-chemistry program. According to the US Environmental Protection Agency, “Green chemistry is the design of chemical products and processes that reduce or eliminate the use or generation of hazardous substances.” Green chemistry is applied at the process level – in this case, API synthesis – to minimize waste and pollution upfront.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance